American Shared Hospital Services (AMS) Earnings Call Transcript & Summary

March 24, 2023

NYSE American US Health Care Health Care Providers and Services earnings 60 min

Earnings Call Speaker Segments

Stephanie Prince

executive
#1

Thanks, Keith, and I appreciate all of you being with us today. This morning, prior to the market opening, AMS released its earnings press release for the fourth quarter of 2022. Should you require one, you'll find it on the company's site, ashs.com, listed under Press Releases within the Investors section. Ahead of handing things to management, I want to offer a few comments about forward-looking statements. Be aware that a number of things we might say during this call regarding anticipated future expectations, plans, and prospects for the company are forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Outcomes could differ materially from what those forward-looking statements suggest because of numerous significant factors, among them those addressed in the company's SEC filings. That covers the company's quarterly report on Form 10-Q for the 3-month period that ended March 31, 2022, June 30, 2022, and September 30, 2022, the annual report on Form 10-K covering the year that ended December 31, 2021, and the definitive proxy statement for the Annual Meeting of Shareholders held on June 21, 2022. No duty is assumed by the company to revise any information in this conference call. At this point I'd like to hand the call to Ray Stachowiak, Executive Chairman of AMS. Ray?

Ray Stachowiak

executive
#2

Thanks, Stephanie, and hello, everyone. We appreciate you being with us for the earnings conference call covering our fourth quarter of 2022. I'll make a few opening comments, and then Craig Tagawa, our President and CFO, will take over to walk through the financials for the fourth quarter. After that, Peter Gaccione, who has just been named Chief Executive Officer of American Shared, will take a few minutes to discuss his priorities and his plans for the company. Once those prepared remarks are done, we'll take your questions. The biggest news we've had lately came on March 10, when the Board of Directors named Peter Gaccione our Chief Executive Officer. You may recall that Peter came aboard at American Shared 6 months ago as our COO, following 40 years in the medical oncology business. He is widely known and highly regarded. A number of us at American Shared have been acquainted with him for many years. He brings deep market knowledge and professional contacts spanning the whole radiation oncology spectrum. I now serve as Executive Chairman of the Board, and I continue to be the company's largest shareholder, holding roughly 20% of the outstanding stock. My intention is to stay actively engaged in company operations as we work side by side to lock in the growth and profitability trends we have firmly established during the year that just ended. We also announced that a search is underway for a new public company CFO to take over from Craig Tagawa, who has served in that role for many years and will stay on as our CFO until a successor is found. Craig will keep serving as President of our company as well as Chief Executive Officer of GK Financing, the subsidiary that is 81% owned by the parent company. American Shared wrapped up a strong year with yet another solid fourth quarter. Revenue in the fourth quarter rose approximately 7% period-over-period and topped $5 million in quarterly revenue for the second time in 2022. Net income climbed 12% to $246,000, or $0.04 per share, capping a year of sustainable quarterly profit trends. In fact, this now marks the eighth consecutive quarter in which earnings per share came in higher than the comparable quarter a year earlier. I expect our profitability to keep going. For the full year, revenue grew 12% to nearly $20 million, and net income rose 6x to $1.3 million, or $0.21 per share. Craig will walk through the details shortly. Our cash balances were up 51% from last year, finishing at $12.5 million on December 31, and our $7 million line of credit is still unused; we believe these funds can be leveraged to invest in over $100 million of advanced radiation equipment. Just recently, we announced our first new order of the year, a $1.3 million agreement with a new customer. Our increased investment in sales and marketing is starting to pay off, and our pipeline is filled with solid opportunities. We believe that American Shared is poised for growth. Craig, I'd like to hand things over to you now so you can walk us through the financials. Craig?

Craig Tagawa

executive
#3

Thanks, Ray, and good morning to all of you. Revenue for the fourth quarter rose 7.4%, reaching slightly more than $5 million, versus $4.7 million during the same quarter a year earlier. As Ray noted, that marks the second occasion this year we've posted quarterly revenue above $5 million. Across the 12 months of the year, revenue grew 12%, totaling $19.7 million. In Florida, fourth quarter revenue from the proton therapy system climbed 33.4% to $2.2 million, largely because average reimbursement was higher period-over-period for the current quarter. Proton therapy fractions totaled 981 in the fourth quarter, down 11.9% from 1,113 in last year's fourth quarter, a movement we view as falling inside a normal quarterly range. Total Gamma Knife revenue fell 7.1% to $2.8 million versus last year's fourth quarter. Domestic Gamma Knife revenue dropped 5.4% to $2 million, while international revenue declined 11.5% to $0.8 million period-over-period. The overall Gamma Knife revenue decline came from fewer procedures, partly offset by higher average reimbursement, which itself resulted from a rise in the average rate at the company's retail sites, driven by a favorable payer mix shift toward more commercial payers. Revenue at same centers in operation, which leaves out 2 Gamma Knife contracts that expired, 1 each in the first and fourth quarters of 2021, fell 6.7% relative to those same centers during the comparable period a year earlier. Total Gamma Knife procedures dropped 10.8% to 329 in the fourth quarter of 2022, from 369 in the fourth quarter of 2021, mainly because of normal cyclical fluctuations and the expiration of 1 contract in the fourth quarter of 2021. Domestic Gamma Knife procedures declined 10% to 243, and international procedures fell 13.1% to 86 for the fourth quarter of 2022 versus 2021. Gamma Knife volumes at same centers in operation decreased 8.4% relative to Gamma Knife volumes at those same centers during the comparable period a year earlier. We look forward to receiving the permits for the Perfexion to Icon upgrade at our Gamma Knife Center in Ecuador. We expect them soon, which would let us begin treating patients in the third quarter. Keep in mind that this will be one of the few Gamma Knife Icon units anywhere in South America. The permit for the new linear accelerator, or LINAC, at our new cancer center joint venture in Puebla, Mexico, is also expected soon. Gross margin for the fourth quarter declined 2.3% to $2.3 million, or 45.1% of revenue, compared with gross margin of $2.2 million, or 47.3% of revenue, in the fourth quarter of 2021. Selling and administrative costs rose 14.7% to $1.4 million, versus $1.2 million last year, mainly because of higher sales and related fees tied to new business opportunities. Operating income came in at $0.6 million, compared with $0.7 million in the fourth quarter of 2021, a decline of 18.4%, reflecting higher operating costs along with selling and administrative expenses. For the fourth quarter of 2022, income tax expense rose 23.3%, reaching $333,000, versus $270,000 in the same quarter a year earlier. Higher earnings in the current period drove most of that rise in income tax expense, along with return to provision adjustments tied to foreign income taxes filed during the current period, plus permanent domestic tax differences that carried through to the close of this year. American Shared Hospital Services reported net income attributable to the company of $246,000, or $0.04 per diluted share, for the fourth quarter of 2022 — up 12.3% from $219,000, or $0.04 per diluted share, in the fourth quarter of 2021. Greater revenues and better average reimbursement rates on both Gamma Knife and PBRT procedures accounted for the gain in net income dollars. For the fourth quarters of 2022 and 2021, fully diluted weighted average common shares outstanding came to 6.3 million and 6.1 million, respectively. Adjusted EBITDA, which is a non-GAAP financial measure, totaled $2,161,000 in the fourth quarter of 2022, basically flat against EBITDA for the fourth quarter of 2021; across the 12 months of 2022, net income attributable to American Shared Hospital Services was $1.3 million, or $0.21 per diluted share, versus non-GAAP net income after the net effect of the debt extinguishment. Noncontrolling interest and income taxes amounted to $0.4 million, or $0.07 per diluted share. For the year, adjusted EBITDA, a non-GAAP financial measure, was $8.2 million, compared with $7.2 million for all of 2021. As of December 31, 2022, cash, cash equivalents and restricted cash stood at $12.5 million, up $4.2 million, or 5.7%, from year-end 2021. Shareholders equity, excluding noncontrolling interest in subsidiaries, was $21.6 million, or $3.50 per outstanding share, at December 31, 2022, against $19.9 million, or $3.28 per outstanding share, at December 31, 2021. To wrap up my remarks, AMS had a good year in 2022, and with our deep resources and solid foundation behind us, we believe we are positioned for future growth. I'll now hand the call over to Peter to discuss his priorities and plans as CEO.

Peter Gaccione

executive
#4

I appreciate that, Craig, and hello everybody. First off, I'd like to express my gratitude to Ray and the Board for placing their trust in me. During his time as CEO, Ray accomplished a tremendous amount in making the company more efficient and setting it up for expansion, and I'm eager now to take American Shared through what comes next. Back on the previous quarterly call, when I was initially brought in front of you, I explained that American Shared offers clinical cancer treatment centers something distinctive: the ability to work with every one of the leading original equipment manufacturers via 1 turnkey vendor inside 1 inventive relationship. That's rare in our sector and ranked among the biggest reasons I chose to become part of the management team at American Shared. Since my appointment as COO in September, my attention has centered on 3 critical objectives. These are: collaborating aggressively with major OEMs to reinforce our commercial ties and build out sales and marketing approaches; engaging with our existing installed base of Leksell Gamma Knife sites and treatment centers to deepen and improve those connections; and creating and rolling out fresh sales and marketing tactics and programs that help our sales teams with lead generation, prospecting, and handling the sales funnel and pipeline. On that last point, our lead generation and the opportunities sitting in our sales funnel have grown considerably across the last few months. My view is that we've achieved strong momentum across all 3 of these objectives. Now, in my role as CEO, I intend to additionally concentrate on elevating global branding and awareness of American Shared among cancer treatment, C-level officers and purchasing committees. It's important that they understand better what we bring to the table and how we at American Shared stand apart from conventional financing alternatives, by demonstrating how simple it is for them to get the newest treatment systems into their department quickly without an onerous financial load, freeing them to direct their financial resources toward other needs inside their facility. Beyond that, before long we'll begin prospecting and tackling new opportunities straight away with bigger national and strategic networks, while still collaborating closely with our strategic OEM partners. We've just brought on a customer advocate who will help us more effectively manage our installed base and back our company's marketing and branding efforts — covering not just American Shared but GK Financing too. Moving forward, you'll notice American Shared appearing far more prominently across major social media platforms, with expanded messaging and information on our websites, and with a greater presence at major radiation oncology and radiosurgery trade shows, both in the U.S. and abroad. We've also just brought in the services of an additional financial sales professional to chase further new business opportunities. Right now we're working on crafting and carrying out growth strategies aimed at making advanced treatment technology simpler for end users to access in places where patients and communities lack adequate service — across the U.S., yes, but also in selected international markets where people wait far too long for treatment. A component of that approach involves forming more joint ventures, for instance the one in Puebla, Mexico, plus making targeted purchases of long-standing cancer centers, and broadening our inventive financial and turnkey offerings so customers gain more flexibility. Everyone here shares the view that AMS holds several avenues for expansion, and thanks to our recently enlarged team structure along with substantial financial backing, we are eager to share news about how things are going in the coming quarters. We appreciate your presence today; that wraps up the formal portion of what we had to present.

Analyst

analyst
#5

We have a lot of respect for what you folks are accomplishing, and I'll probably take a bit more time on this since, over at Ford Ashford, our view is that folks know your business better, and because of that, there will be far more receptiveness toward your company. So, let me walk through a few figures. Please don't be courteous with me. Be genuinely blunt. Should I get anything incorrect, halt me and set me straight right away; yet the humorous point—though it isn't truly humorous—is that the market appears not to grasp regarding your company that depreciation is an expense that isn't cash; thus, when I simply examine the figures, it appears that, each year, you generate roughly $7 million in cash flow from operations along with $8.2 million in EBITDA annually, so that's approximately slightly above $2 million each quarter in EBITDA, so a $17 million market cap, $7 million in cash flow from operations. You're at 2.42x cash earnings, which, in my view, positions you as the least expensive public company in the United States on an enterprise value to cash flow basis, which is somewhat intriguing considering how steady your business is once you put together proton beam therapy with Gamma Knife procedures; that's intriguing.

Ray Stachowiak

executive
#6

Well, Harry...

Analyst

analyst
#7

Up to this point in the figures, have I made any incorrect statement?

Ray Stachowiak

executive
#8

No, nothing you said was wrong. <<inaudible>> along with what you've pointed out. On our previous quarterly conference call, I stated that I hold a strong conviction that our value is understated. When you examine any one of those metrics alongside the overall market, or against a business that perhaps hasn't expanded a great deal previously, yet you're able to describe our company's future in such a favorable way, our value truly is understated.

Analyst

analyst
#9

Yeah. So, at 2.4x cash flow — and I'm not saying this to be flippant — even a neighborhood laundromat wouldn't go for 2.4x cash flow from operations, and definitely not a medical business that's well respected. So it's really striking that even in a steady state, where the market might assign, say, an 8x multiple, if you subtract the cash you hold — which, based on your filings, my rough estimate right now, just an estimate, a guesstimate, is that you likely have somewhere between $14 million and $15 million in unrestricted cash as of today. And if I look at your balance sheet, it appears you've got $14 million in total debt when you add long-term debt plus the current portion of long-term debt. So basically, using only the cash sitting on the balance sheet, if you decided to, you could be nearly debt free entirely, I think. Is that right?

Ray Stachowiak

executive
#10

I'd say you're pretty much right on those numbers. Yes.

Analyst

analyst
#11

Okay. So to wrap up what those figures imply, since you're paying roughly $1 million annually in interest expense, the business's actual cash generation is nearly equal to your EBITDA, or around $8 million in cash flow from operations. The reason I describe your real cash flow from operations — after adding back interest expense, which could instantly be offset by cash on hand — as such is that depreciation makes up such a massive portion of cash earnings. That's why it appears the genuine cash flow from operations, once you subtract interest expense (something you could readily accomplish and could use right now to retire debt), truly amounts to $8 million per year. If you're looking at $8 million on an annual basis, the multiple works out to roughly 2x cash flow from operations — take 2 and multiply it by $8 million, and you get $16 million, set against a market cap of $17 million. I have to say, that's pretty extraordinary; it actually beats a 2.4x cash flow from operations multiple. In other words, if you put an 8x multiple on that $8 million for a company in steady state, its market cap should be $64 million. Then, following your vision, if growth happens, and considering how much the market loves medical companies, a 15x multiple would put your market cap at $120 million, assuming double-digit expansion. I just wanted us to see eye to eye conceptually on what's at stake here. And with all that in mind, this looks like a prime M&A candidate. You made a good point that having cash on the balance sheet gives us a lot of flexibility — roughly $100 million that we could put toward more sophisticated radiological equipment. So my main question is this: from a strategic standpoint, how does the company think about the sales psychology of, for example, pitching the Long Beach situation to physicians working in private practice — together with the kinds of risks you're so skilled at managing — and then developing a proton beam therapy room, as opposed to, for instance, particular hospitals that, as you know very well, are always in need of cash? Also, what about finalizing a sale and leaseback deal where a hospital that's already running, with cash flow from operations that's easy to measure, basically buys either a controlling or a minority piece under a sale and leaseback type of structure, or just acquires a straight minority position so the hospital can unlock cash? From a strategic standpoint, how do you see those two different sales cycles?

Ray Stachowiak

executive
#12

We're probably — let me say we aren't really inclined to go to health-care systems and chase sale-leaseback arrangements. If you do that kind of thing, what you're essentially doing is money-over-money financing, and we think our company delivers far more added value than that sort of offering. So our focus is going to be on that route of supplying radiation oncology equipment. Health-care systems find this kind of undertaking extremely demanding on their capital. Picture a sizable health-care provider: requests for capital expenditures totaling $100 million might land on the finance officer's desk over the course of a year, but only $25 million is actually available to hand out. So where do they direct those funds? Partnering with American Shared lets us expand that capital budget, which means they can enter the market with this advanced technology much faster than their competitors, remain competitive, and hold their position as a leader in cancer treatment throughout the service area they serve. Is that clear?

Analyst

analyst
#13

That all makes sense, and I'm sorry for posing something close to what I already asked, just framed a bit differently. But has it ever crossed your mind, instead of taking control of the proton beam therapy center, to hold minority positions of 20% to 40%, which could let you spread out more geographically and simply have a more varied set of centers, without needing such a massive outlay — say, $100 million or $150 million, and so on?

Ray Stachowiak

executive
#14

Should the circumstances call for that, and should that be what serves the customer's needs, then I'd say yes — we would be quite open to those kinds of situations.

Analyst

analyst
#15

The math here is really intriguing, since if you're expanding at 30% to 50% — maybe 47-point-something based on additional data, or nearer to 30-something for proton beam therapy — purely in mathematical terms, a moment arrives when the expansion of proton beam therapy becomes so significant that it surpasses the domestic business decline, the drop in the Gamma rate. Naturally, though, you're constrained to the Orlando center. Still, it appears that the optionality — the embedded optionality sitting on your balance sheet, which I'd estimate at $14 million, $15 million in unrestricted cash — is simply remarkable. So I'll let another person pose a question. Yet before I finish, might you provide a bit of color on — it appears the mix of payers — of commercial payers has genuinely enhanced the cash flow from proton beam therapy. Could you speak to us, offer some intuition regarding where that originates or what causes the rise in commercial payers relative to Medicare?

Ray Stachowiak

executive
#16

Okay. That's an excellent question, Harry. I'll redirect it to our resident expert, Craig Tagawa, who tracks that very carefully. Craig, would you comment on that?

Craig Tagawa

executive
#17

Certainly. Okay, several elements play into this. First, it clearly relates to which kinds of payers are involved—meaning which categories of patients are being seen and what conditions they present with. When a greater share of conditions involves an elderly group, with Medicare as the main coverage source, then generally you'll see a reduced average reimbursement rate. Medicare's payments are mostly below what our HMOs and PPOs provide; so it's partly about the condition and partly about which category of patient happens to walk in. And this moves in cycles. You can't forecast it.

Analyst

analyst
#18

Got it. And this is another pure shot in the dark on my part, just speculation, but it appears that as additional applications for proton beam therapy are discovered beyond oncology, that is essentially, by its very nature, bringing in a patient who is younger from a demographic standpoint, or that is merely a guess.

Analyst

analyst
#19

To start with, that was superb. I must say, those were superb questions from the earlier — many of my own questions got answered by that previous person, and those are excellent questions. Has your team ever thought about simply repurchasing the shares? At the current prices, it would appear to make — my initial question is, indeed, have you thought about a buyback of shares at these prices? To me it simply looks incredibly cheap. And so what if you are removing stock from the float? Why not let that accrue to the advantage of existing shareholders?

Ray Stachowiak

executive
#20

Well, Tony, that is an excellent question. And I need to sidestep it somewhat given the forward-looking criteria, yet I can promise our shareholders and investors listening on this call that, across the past 3 years, my tenure as CEO with American Shared, I delivered that degree of experience as a CEO to the organization. I had 19 years of earlier experience as a CEO at the firm I started, and I can promise our shareholders and investors that numerous strategic alternatives for our company's future have been discussed and chased. And we are where we are at present, and we believe we are best positioned genuinely to serve our shareholders. And should they remain with us, I believe they will enjoy a solid return on their investment. I've said on earlier calls and in Harry's questions, I believe we are a stock that is undervalued by virtually any metric. You examine our P/E ratio, and it appears that with each quarter that passes, our P/E ratio becomes smaller. If you examine the EBITDA figures, the increase in EBITDA from $7.2 million in 2021 to $8.2 million in 2022, with no truly new revenue streams arriving. And then you examine the resources we are directing into our sales and marketing efforts, those resources will pay off through securing new agreements and new revenue streams. As everybody knows, if they know our company, we have long sales cycles at our company. It's a complicated sale, but we have truly, truly, truly strong resources to meet that challenge.

Analyst

analyst
#21

Correct; my next question concerns what I believe is partly why those trades in the stock happened: there is zero analyst coverage. I'm not certain whether — and everyone is aware that in this market, or within the micro cap space, you must pay something, essentially you have to — even though nobody will admit it, you essentially must pay something to obtain research coverage. Has any step been taken to secure some — even certain paid research services, which in my view are quite decent, would beat having none, since at minimum your name gets out there. I'm simply wondering, has that been — I'm unsure whether any attempt has been undertaken to draw in some form of analyst coverage?

Ray Stachowiak

executive
#22

Those efforts, I'd say, are beginning to happen. Let me add that in a way I'm an old-school type of investor: prior to promoting any investment, let's show a strong, stable base, consistent growth, consistent profitability, a foundation to rely on, a story to offer, a case to bring before the financial analyst community.

Analyst

analyst
#23

I'll take a somewhat different view from yours on that point, and here's why: you've just explained — and the earlier questioner gave a solid rationale too — setting aside growth entirely. Merely the state we're in at present would be ample justification to purchase the shares, and investors purchase shares for a variety of motives. Certain equities are growth equities. Certain equities are asset plays. And in this particular case, I believe, what you have is an asset play at this moment combined with a possible growth play. So I'll push back somewhat by asking why pursue analyst research at this point, given that you haven't demonstrated sustained growth. What you have demonstrated, though, is the capacity to keep producing remarkable EBITDA in relation to your market cap. So that's all I'll say about it. I'm not attempting to pick a fight. I'm merely noting that I believe it's an error to refrain from seeking analyst coverage, since I believe you fit into numerous buckets, and the bucket at present is plainly an asset play. In any case, many thanks. I'm grateful that you took the questions.

Ray Stachowiak

executive
#24

Tony, allow me to absorb all of that and think it over. I believe that's really — that's truly excellent feedback. And I prefer to regard myself as a person who listens carefully, all right, and is always receptive to input. So I'll take that as advice, as feedback. Okay?

Tony Kamin

analyst
#25

Hearing about the broad plan you've got now—covering closer collaboration with manufacturers plus fresh initiatives aimed at reaching end customers—was genuinely pleasant. That's really good to hear. It comes across as quite thorough. My initial question, I suppose, concerns the new customer tied to that $1.3 million sale you announced. Could you describe what kind of customer that is? Would it be a hospital? Or perhaps a different type of organization? And does it involve Gamma Knife equipment, or is it something else?

Ray Stachowiak

executive
#26

Yes. I believe I'll hand that one over to Peter. That said, identifying that customer by name likely isn't possible, given the nondisclosure agreements we occasionally have in place with our clients. But...

Tony Kamin

analyst
#27

Which is exactly the reason I chose the word characterize over name.

Ray Stachowiak

executive
#28

Peter, would you describe that client for us?

Peter Gaccione

executive
#29

Absolutely, absolutely. Yes, I appreciate you asking that. Yes, I'd describe this as having two parts. There's a cancer treatment center run as a joint venture, and it does operate a Gamma Knife, plus it's a joint venture alongside a big hospital affiliate nearby. And here's what the situation was: they had to replace an older version of the system with a more recent one, and we could advise them and find an inventive approach to get it done, since just 2 options existed for them — either get it done so their patient base could grow and a strong, excellent radiosurgery program could keep going, or consider shutting it down, and nobody wanted that. And thanks to our backing and ingenuity, it got done, and the results turned out very well.

Tony Kamin

analyst
#30

Great. And...

Ray Stachowiak

executive
#31

Just before you move on to your next question, let me add a bit of color to that. That local hospital which belongs to that joint venture is part of a bigger health-care system. And the people in the C-suite of that health-care system have witnessed what American Shared's capable of doing to this local hospital they own; and thus, it's opened the doors to the C-suite within that health-care system, okay? That's some of the intangible benefits. Small order, but it's some of the intangible benefits we're accruing.

Tony Kamin

analyst
#32

So, in this quite challenging credit and interest rate climate for it — I'm certain many of your eventual end-user prospective buyers are pondering how to obtain financing in a fairly efficient and sensible manner; therefore, I suppose I'm interested regarding what you've experienced there, and conversely, I'd imagine the same applies to Elekta and your other possible manufacturing partners, in that they recognize they must assist the end-user customer in becoming more inventive about ways to reach the technology in a sensible economic manner. Have you observed shifts due to what's been happening with the economy and interest rates that have been beneficial in that regard? And does that awareness exist on both the manufacturer and end-user sides?

Ray Stachowiak

executive
#33

Yes. I'll have Peter respond to that. Broadly speaking, I'll simply state, yes, I believe we've begun to see that. But Peter, would you like to address that question a little?

Peter Gaccione

executive
#34

Certainly, certainly. That's a very — it's a solid inquiry, and honestly there's quite a bit packed into it. As you're aware, I've spent more than 40 years working in this field. My credibility is strong, and I'm acquainted with numerous key decision makers and opinion leaders — not just at the practice level among physicians and at the cancer institutes, but likewise within senior management and sales ranks at the many OEMs we work with. What I can tell you is that we're receiving considerable interest and numerous calls from lots of folks in the industry who simply know that I'm now here at American Shared. They're asking to learn more about — oh, okay, we realize you're over there. We realize you've been in this industry, and that's when discussions begin regarding the financing and the distinctions we provide for funding. So exactly like in the case of this situation where our first order came in, they reached out to us purely because of that. And we're getting many calls for that reason; so much of it stems from people who know you; it's quite a small community. In this business everybody knows everybody, past reputations, credibility. And this is a different approach, as I mentioned. It's uncommon in this industry, and we're striving to spread that awareness to everyone. But it's a fascinating dynamic. And I can tell you, I truly see things occurring just from, again, our pipeline and leads and activities that we're examining.

Tony Kamin

analyst
#35

Ray, I jotted some of this down. I'm hoping I got your words right, but my understanding is you described the pipeline as being full of strong possibilities. Could either of you expand on that a bit, or provide additional detail about the pipeline? Does it span — does it cover multiple products? Is it...

Ray Stachowiak

executive
#36

Yes, that's quite simple for me to lay out for you; and we've discussed growing what we offer and what our approach is, along with diversifying somewhat beyond merely supplying Gamma Knives and proton beams. So allow me to address what sits in our pipeline from a few angles; it holds a wide variety of product offerings; it holds Gamma Knives, linear accelerators, MR/LINACs, and additionally the supplying of proton beam systems. And that aligns with the growth of all we've been discussing, let's broaden what we offer. We've got domestic opportunities, plus we've got international opportunities too. We've got opportunities involving new business clients, new clients that haven't been ours before, and we've got opportunities we're chasing with clients we already have, deepening those ties; we've got business model structures that might differ; they might be, I'd say, the conventional arrangements we've used previously, where we supply a Gamma Knife, say, at X dollars per treatment. Or perhaps we supply that Gamma Knife in exchange for some percentage of the revenue that the health-care system brings in from that Gamma Knife. We're also chasing joint ventures in which we hold ownership, at times majority, at times minority, within a joint venture relationship; and one of the excellent aspects of that kind of relationship is that those relationships lack contracts or agreements that lapse, that carry a contract expiration date. So they're extremely long-term focused; that plus all those kinds of opportunities are present in our pipeline.

Tony Kamin

analyst
#37

No, that’s excellent. Just a couple more brief items. First, lately in the media, I’ve come across a growing quantity of pieces discussing Gamma Knife — Gamma Knives overall expanding; and I’m not entirely certain what exactly they mean, whether it’s cases or abilities or something else increasing in ’23; it seems as though for several years, I hardly saw anything on that; yet once again, there has been some coverage regarding growth. Are you observing that? Or is it merely — is that accurate?

Ray Stachowiak

executive
#38

I’ll send that one over to Peter. He is our in-house authority on the Gamma Knife sector.

Peter Gaccione

executive
#39

Yes, what you have been observing is completely accurate. During the early period of radiosurgery, the Gamma Knife performed very strongly for some time. After that, as is common knowledge, with linear accelerators, radiosurgery began to close the gap somewhat. However, we—along with other vendors too—are indeed witnessing a rise in both the Gamma Knife modality and Gamma Knife treatment. Much of this relates to the benefits provided through software, through treatment planning, and through same-day imaging and treatment; therefore, numerous improvements have been made to that system, and it has genuinely rebounded; so your statement is right when you mention hearing about growth in Gamma Knife type treatments, not just within the U.S., but across the globe. And naturally, this also flows through to the installed base when the time comes for upgrades too.

Tony Kamin

analyst
#40

No, that's thrilling. Moving on to my final question, which I sense I've raised for a number of years, yet it matters greatly when it comes to scale. Could you describe the current demand for additional proton systems? Clearly, quite a few years have passed since the one you put in at Orlando, and I'm aware shareholders genuinely hope for a repeat performance in another location. Would you speak broadly about proton?

Ray Stachowiak

executive
#41

Sure, what I can say is that proton beam opportunities remain something we actively chase. I won't say much regarding anything forward-looking, but you can be certain we've likely examined a greater number of proton beam opportunities over the past 9 months than I can remember, either as a shareholder dating back to 20 — or as a Board member dating back to 2009. Frankly, a portion of those simply don't justify our investment, since the partnership we're seeking to enter — to join forces with — carries too much CapEx spending to sustain the revenue streams that would result; therefore, we're assessing these opportunities with great care and intelligence. And we feel a handful exist that satisfy our criteria.

Harry Long

analyst
#42

Sirs, since nobody else seems to be waiting in line, I figured I'd use some extra time. Let me start with a few broad questions, then drill down very specifically. The thing everyone's thinking about, I suppose, is that besides Ray being a fantastic investor, if you look at the money sitting on the balance sheet and the flexibility that gives you, our projection is that 12 to 15 months out, there will be no less than $20 million to $23 million in cash — more than the present market capitalization of your business. So what we want to know is this: with Ray's knowledge plus the knowledge Peter and Craig bring, would you acquire other businesses that generate cash flow, essentially turning into a conglomerate along the lines of a small Berkshire Hathaway, and then employ those cash flows for diversification while also deploying that balance sheet cash when opportunities arise? Or would you remain focused on what you know best, proton beam therapy? That's truly the central question for us. Between those 2 routes, which one do you want to pursue?

Ray Stachowiak

executive
#43

Yes. It's unlikely we'll turn into the Berkshire Hathaway of radiation oncology equipment.

Analyst

analyst
#44

That said, your plate is full with plenty of other ventures. I've been tracking what you've done professionally. Your activities extend well beyond this.

Ray Stachowiak

executive
#45

Let me push back a bit on what you're assuming about our cash; sure, by EBITDA as a gauge, our free cash flow might sit around $7 million to $8 million annually, yet spending the cash we hold that way wouldn't be wise, since we'll likely face some CapEx outlays during 2023 — upgrades are taking place in Ecuador, and a new location is being added in Puebla. It's possible we won't fund those purchases entirely — 100% of them, that is; some portion of equity will likely be contributed by us. That means equity-side CapEx will feature in those investment opportunities. So let's stay prudent about deploying the resources at our disposal. One thing I'll mention: a standout achievement of mine during my time at Shared Imaging involved acquiring equipment valued at $20 million, $25 million, $30 million annually, and at the point when I purchased the company, I held 100% ownership, and never once did I have to dilute my equity stake while that CapEx spending was being financed. Banking relationships were how I built that up. Our ties with Fifth Third Bank, we feel, are strong. Fifth Third Bank, in our view, is a solid institution, and when it comes to engineering our growth financially, we'll exercise prudence.

Analyst

analyst
#46

That works out well, since it brings me to what I wanted to ask next. I happened to be reviewing a few of the debt covenants you folks listed in the annual report you filed most recently, and from what I can tell, there's a total debt to EBITDA covenant sitting at 3x. That said, do any covenants currently in place stop the company, whether right now or down the road, from issuing a dividend to holders of common stock?

Ray Stachowiak

executive
#47

Our banking relationship includes a restriction addressing the amount of dividends we're able to distribute to shareholders. A provision allowing it does exist, though it comes with limits.

Analyst

analyst
#48

And on that note, I'm curious — it seems totally fair that, assuming you've got unrestricted cash available, enough to cover all your debt, which I think you either have or will soon, I'm wondering whether they might be willing, or whether the company might be willing, to discuss amending that confidence clause so that if unrestricted cash sits on the balance sheet — cash that could genuinely cover the whole debt, not that you'd want to, but if you decided to — they'd relax a few of those dividend restrictions. Anyway, moving on, here's a very particular question. I'm only raising it since it sounds like it's full speed ahead on proton beam therapy, if that's feasible. In your annual report I saw a note about $2.25 million in deposits for 2 Mevion S250i proton beam therapy systems, and those were written down to zero. My question, though, is this: even if for accounting purposes those deposits got written down to zero, if you decided to buy 1 or 2 systems, would Mevion still count those deposits toward the purchase price? So let's separate the accounting side — having them written down on your balance sheet — from the commercial relationship.

Ray Stachowiak

executive
#49

Yes, that's the answer. Those deposits are still on our account with Mevion. So should we buy a proton beam system from Mevion, that deposit would be credited to us. I want to note that the amounts we wrote off in December — in the fourth quarter of 2020, rather — did include some capitalized interest on those deposits. That capitalized interest piece, then, would not be on our account with Mevion. Does that make sense?

Analyst

analyst
#50

Okay, that makes sense. Then a follow-up — regarding that $2.25 million in deposits, is Mevion requiring you to split it evenly across 2 separate systems? Or, if you wanted, could you put those 2 deposits together as 1 deposit toward a Mevion 250i system?

Ray Stachowiak

executive
#51

I believe it would be fair for Mevion to expect that each deposit applies to its own respective order.

Analyst

analyst
#52

All right. I also picked up on the fact that Mevion keeps bringing up a 250 fit proton system, plus a few other items. That said, does the S250i remain the most advanced option, or might this deposit be put to use before any upgrades arrive for the S250i? My reason for asking is simply this: if we're going all in on proton beam therapy, instead of dividends or purchases beyond gynecologic oncology, or aiming at this like a laser.

Ray Stachowiak

executive
#53

Yes, I'd say it's a reasonable assumption that, should we buy a proton system from Mevion, we enjoy solid ties with Mevion. And I believe both sides would show flexibility regarding the way those deposits get used and regarding the precise configuration for buying the proton beam system, and how that configuration would look. There are all sorts of extra features, as with any Mevion proton beam system they offer; and we are committed, if and when we accept delivery of such a system, we are committed to altering the equipment we presently have on order with them so we obtain the newest technology; and Mevion would back that kind of flexibility; our relationship with them is strong.

Analyst

analyst
#54

That's great to hear, really great to hear. And in addition, is there anything new, if anything, regarding Long Beach Equipment LLC, which from what I understand isn't anticipated to do anything? But I was just wondering whether there had been any additional movement in that area.

Ray Stachowiak

executive
#55

Yes, I'll just make a comment. The marketplace in that region has been very challenging, one that faces challenges from the various health-care systems in that area and, frankly, from a search for a suitable facility to place the operation in the center.

Analyst

analyst
#56

Yes, yes. That's quite fascinating, actually. Another point I wanted to bring up — and this is merely a suggestion. I realize you receive countless absurd requests constantly, so my apologies in advance for what I'm about to say. Still, since the majority of folks aren't immersed in this proton beam therapy field the way you are — and although I found your overview of various equipment makers truly excellent, covering names such as Mevion, IBA, Varian and Hitachi, ProNova, Sumitomo, ProTom, Mitsubishi, and so on — my hope was that perhaps down the road, the annual report might include some dialogue about the various nonhospital participants. While conducting a bit of research recently in Texas, it struck me as quite notable to observe, for example, what unfolded involving Concord Medical, which acquired a 20% stake in the MD Anderson proton beam therapy center and afterward shed that stake, along with cases like US Oncology, which as you're aware is a McKesson subsidiary and which appears to — I haven't any clue regarding their precise connection to Texas Center for Proton Therapy in North Texas — but just a few of these — it appears there are fewer than 40 proton beam therapy machines, and perhaps that figure will reach 42 or 45 once some building is finished, yet across the entire United States, so if there were any conversation about the current state of the industry, whether during this call or within an annual report, that would be enormously valuable. Anyway, we're simply enormous supporters of yours. We greatly admire the cash flow generation, and we look forward to watching your progress.

Ray Stachowiak

executive
#57

Thanks, Harry. I value your remarks and your inquiries and your input. Much appreciated.

Ray Stachowiak

executive
#58

Thanks, operator. I also want to thank each of you for being with us today; the Q&A portion was productive. Your input and inquiries mean a lot to us, and I hope our answers proved useful. The consistent expansion we've achieved makes us quite proud, along with the profit trajectory we've built, and as we said, you can likely detect from the sound of our voices how enthusiastic we are about what lies ahead for American Shared; we genuinely feel that our recently realigned leadership group, the substantial financial wherewithal at our disposal, and what we've put into sales and marketing leave us strongly positioned for ongoing growth and profitability; we can't wait to talk with you once more when our Q1 numbers come out in mid-May. Should anything come up before then, reach out to us directly. Take care and remain healthy. Farewell.

Operator

operator
#59

Thanks a lot. That brings the call to a close. We appreciate your joining us for today's presentation. You're free to hang up at this point.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete American Shared Hospital Services transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to American Shared Hospital Services earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in American Shared Hospital Services or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.